Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Samer Al Hadidi to Humans

This is a "connection" page, showing publications Samer Al Hadidi has written about Humans.

 
Connection Strength
  
 
 
1.879
  
  1. Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Tricot G, Shaughnessy J, Zhan F, Sawyer J, Siegel ER, Zangari M, Barlogie B, van Rhee F. Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2024 Nov; 99(11):2222-2224.
    View in: PubMed
    Score: 0.040
  2. Patel TH, van Rhee F, Al Hadidi S. Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):762-769.
    View in: PubMed
    Score: 0.040
  3. Al Hadidi S, Heslop HE, Brenner MK, Suzuki M. Bispecific antibodies and autologous chimeric antigen receptor T?cell therapies for treatment of hematological malignancies. Mol Ther. 2024 Aug 07; 32(8):2444-2460.
    View in: PubMed
    Score: 0.040
  4. Altarawneh H, Manasrah M, Al Shanableh Y, Saed Aldien A, Manasrah MA, Khan S, Altarawneh L, Al-Kraimeen LM, Al Kasaji F, Alareeki A, Al Hadidi S. Authorship characteristics of hematology and oncology education chapters: A comprehensive analysis. J Cancer Policy. 2024 Jun; 40:100484.
    View in: PubMed
    Score: 0.040
  5. Elemian S, Al Hadidi S. Targeting GPRC5D in multiple myeloma. Expert Rev Anticancer Ther. 2024 May; 24(5):229-238.
    View in: PubMed
    Score: 0.039
  6. Al Hadidi S. Clinical trials of T-cell re-directing therapy in plasma cell precursor conditions. Eur J Cancer. 2024 May; 203:114045.
    View in: PubMed
    Score: 0.039
  7. Rafae A, van Rhee F, Al Hadidi S. Perspectives on the Treatment of Multiple Myeloma. Oncologist. 2024 Mar 04; 29(3):200-212.
    View in: PubMed
    Score: 0.039
  8. Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Bailey C, Smith R, Panozzo S, Alapat D, Cottler-Fox M, Tricot G, Shaughnessy JD, Zhan F, Sawyer J, Barlogie B, Zangari M, van Rhee F. Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood Adv. 2024 02 13; 8(3):703-707.
    View in: PubMed
    Score: 0.039
  9. Abusamak AA, Abusamak M, Al-Abbadi M, Rayyan A, Oran O, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Cliff ERS, Al Hadidi S. Use of subjective minimizing language at hematology and oncology conferences: A systematic review. J Cancer Policy. 2024 Mar; 39:100461.
    View in: PubMed
    Score: 0.038
  10. Alrawabdeh J, Alzu'bi M, Alzyoud M, Odeh N, Hamadneh Y, Mian H, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Russler-Germain DA, Mehra N, Baggio D, Cliff ERS, Al Hadidi S. Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review. JNCI Cancer Spectr. 2023 10 31; 7(6).
    View in: PubMed
    Score: 0.038
  11. Fahmawi S, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines. J Cancer Policy. 2023 09; 37:100433.
    View in: PubMed
    Score: 0.037
  12. Mazahreh F, Mazahreh L, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023 07 11; 7(13):3069-3074.
    View in: PubMed
    Score: 0.037
  13. Chakraborty R, Al Hadidi S. Intent Matters: Real-World Applicability of Idecabtagene Vicleucel Usage in the United States. J Clin Oncol. 2023 07 10; 41(20):3657-3658.
    View in: PubMed
    Score: 0.037
  14. Mazahreh F, Al-Hader AA, Al Hadidi S. Visa Constraints and Career Choices for Oncologists. J Natl Compr Canc Netw. 2023 03; 21(3):332-334.
    View in: PubMed
    Score: 0.037
  15. Al Hadidi S, Abu Zaid MI, Mustafa Ali M. Institutional disparities in the distribution of the American Society of Clinical Oncology grants. J Cancer Policy. 2023 03; 35:100404.
    View in: PubMed
    Score: 0.036
  16. Al Hadidi S, van Rhee F. Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial. J Clin Oncol. 2023 03 20; 41(9):1788.
    View in: PubMed
    Score: 0.036
  17. Al Hadidi S, Cliff ERS. CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma. Eur J Cancer. 2023 03; 182:1-2.
    View in: PubMed
    Score: 0.036
  18. Syaj S, Al-Kraimeen L, Akhdar M, Abushukair H, Mohty R, Al Hadidi S. Gender and early-career faculty disparities in hematology and?oncology board review lecture series. Blood Adv. 2022 12 27; 6(24):6213-6218.
    View in: PubMed
    Score: 0.036
  19. Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardan A, Radhakrishnan SV, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D'Souza A, Zangari M, van Rhee F, Mohan M. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transplant. 2023 04; 58(4):443-445.
    View in: PubMed
    Score: 0.036
  20. Sawalha L, Kelkar AH, Mohyuddin GR, Goodman AM, Gagelmann N, Al Hadidi S. Analysis of repeated roles in editorial boards at oncology focused journals. J Cancer Policy. 2023 03; 35:100380.
    View in: PubMed
    Score: 0.036
  21. Hussain M, Khan F, Al Hadidi S. The use of bone-modifying agents in multiple myeloma. Blood Rev. 2023 01; 57:100999.
    View in: PubMed
    Score: 0.035
  22. Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Tricot G, van Rhee F, Al Hadidi S. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA Netw Open. 2022 08 01; 5(8):e2228877.
    View in: PubMed
    Score: 0.035
  23. Thalambedu N, Al Hadidi S. Thromboprophylaxis in multiple myeloma. Leuk Lymphoma. 2022 12; 63(12):2807-2815.
    View in: PubMed
    Score: 0.035
  24. Ali MO, Al Hadidi S. High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma. Transplant Cell Ther. 2022 09; 28(9):572-580.
    View in: PubMed
    Score: 0.035
  25. Al Hadidi S, Zangari M, van Rhee F. Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions. JAMA Oncol. 2022 06 01; 8(6):823-824.
    View in: PubMed
    Score: 0.035
  26. Abushukair H, Syaj S, Ababneh O, Qarqash A, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Al Hadidi S. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenstr?m's Macroglobulinemia: A systematic review and meta-analysis. Am J Hematol. 2022 07; 97(7):942-950.
    View in: PubMed
    Score: 0.034
  27. Hadidi SA. Melflufen in multiple myeloma: the conclusion matters. Lancet Haematol. 2022 04; 9(4):e244.
    View in: PubMed
    Score: 0.034
  28. Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA Netw Open. 2022 04 01; 5(4):e228161.
    View in: PubMed
    Score: 0.034
  29. Al Hadidi S. The Use of Modified Surrogate End Points in Cancer Clinical Trials. Cancer Invest. 2022 01; 40(1):14-16.
    View in: PubMed
    Score: 0.033
  30. Al Hadidi S, Kamble RT, Carrum G, Heslop HE, Ramos CA. Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies. Blood Adv. 2021 11 23; 5(22):4630-4633.
    View in: PubMed
    Score: 0.033
  31. Al Hadidi S, Yellapragada S. Treatment Options for Relapsed and Refractory Multiple Myeloma: A Luxury or a Challenge? JAMA Oncol. 2021 10 01; 7(10):1449-1450.
    View in: PubMed
    Score: 0.033
  32. Nanah A, Al Hadidi S. Bing-Neel Syndrome: Update on the Diagnosis and Treatment. Clin Lymphoma Myeloma Leuk. 2022 03; 22(3):e213-e219.
    View in: PubMed
    Score: 0.033
  33. Al Hadidi S, Dongarwar D, Salihu HM, Kamble RT, Lulla P, Hill LC, Carrum G, Ramos CA, Heslop HE, Usmani SZ. Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leuk Lymphoma. 2021 12; 62(13):3256-3263.
    View in: PubMed
    Score: 0.033
  34. Awidi M, Al Hadidi S. Participation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed Solutions. JCO Oncol Pract. 2021 05; 17(5):265-271.
    View in: PubMed
    Score: 0.032
  35. Al Hadidi S, Ramos CA. Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies. Leuk Lymphoma. 2021 06; 62(6):1522-1524.
    View in: PubMed
    Score: 0.032
  36. Al-Hadidi SA, Lee HJ. Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma. JCO Oncol Pract. 2021 02; 17(2):64-71.
    View in: PubMed
    Score: 0.031
  37. Al Hadidi SA, Lee HJ. Pembrolizumab for the treatment of Hodgkin Lymphoma. Expert Opin Biol Ther. 2020 11; 20(11):1275-1282.
    View in: PubMed
    Score: 0.031
  38. Al-Hadidi SA, Chuang HH, Miranda RN, Lee HJ. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 02; 21(2):e105-e111.
    View in: PubMed
    Score: 0.031
  39. Al Hadidi S, Mims M, Miller-Chism CN, Kamble R. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs. Ann Intern Med. 2020 08 18; 173(4):320-322.
    View in: PubMed
    Score: 0.030
  40. Al Hadidi S, Miller-Chism CN, Kamble R, Mims M. Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e579-e589.
    View in: PubMed
    Score: 0.030
  41. Daher H, Towfiq B, Al Hadidi S. Gradually Worsening Pruritic Plaques. JAMA Oncol. 2018 Apr 01; 4(4):573-574.
    View in: PubMed
    Score: 0.026
  42. Al Hadidi S, Aburahma A, Badami S, Upadhaya S. PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials. Oncol Res Treat. 2018; 41(4):226-235.
    View in: PubMed
    Score: 0.026
  43. Al Hadidi S. Delayed Adjuvant Chemotherapy and Survival After Lung Cancer Surgery. JAMA Oncol. 2018 02 01; 4(2):262.
    View in: PubMed
    Score: 0.026
  44. Al Hadidi S. Timing of Pregnancy and Survival in Women With Breast Cancer. JAMA Oncol. 2018 01 01; 4(1):131.
    View in: PubMed
    Score: 0.026
  45. Daher H, Al Hadidi S. Dysphagia lusoria presenting as epigastric pain. BMJ Case Rep. 2017 Dec 05; 2017.
    View in: PubMed
    Score: 0.025
  46. Elounais F, Aburahma A, Alkotob ML, Al Hadidi S. Ventricular tachycardia after initiation of fingolimod. BMJ Case Rep. 2017 Sep 27; 2017.
    View in: PubMed
    Score: 0.025
  47. Al Hadidi S, Wu K, Aburahma A, Alamarat Z. Family with clots: antithrombin deficiency. BMJ Case Rep. 2017 Aug 11; 2017.
    View in: PubMed
    Score: 0.025
  48. Osman M, Al Salihi M, Abu Sitta E, Al Hadidi S. A rare case of Epstein-Barr virus mucocutaneous ulcer of the colon. BMJ Case Rep. 2017 Jul 06; 2017.
    View in: PubMed
    Score: 0.025
  49. Al Hadidi S. Aspirin and Cancer Risk. JAMA Oncol. 2016 10 01; 2(10):1371-1372.
    View in: PubMed
    Score: 0.023
  50. Al Hadidi S, Haddad RA, Abed F, Bachuwa G. Penile gangrene as a sign of uncontrolled diabetes mellitus. BMJ Case Rep. 2016 Feb 05; 2016.
    View in: PubMed
    Score: 0.022
  51. Al Hadidi S, Shaik Mohammed T, Bachuwa G. Unusual presentation of uterine leiomyoma. BMJ Case Rep. 2015 Apr 09; 2015.
    View in: PubMed
    Score: 0.021
  52. Al Hadidi S, Towfiq B, Bachuwa G. Dystextia as a presentation of stroke. BMJ Case Rep. 2014 Nov 20; 2014.
    View in: PubMed
    Score: 0.021
  53. Hadidi SA, Shastri R. Vanishing Lung Syndrome. J Am Osteopath Assoc. 2017 08 01; 117(8):541.
    View in: PubMed
    Score: 0.012
  54. Patel T, Chen C, Al Hadidi S, Kadry Y, Sridhara R, Purcell E, Wisch L, Retzlaff J, Foti M, Pazdur R, Kluetz P, Gao J. Reflections and Roadmaps: Career Development beyond the FDA-AACR Oncology Educational Fellowship. Clin Cancer Res. 2024 Aug 01; 30(15):3144-3146.
    View in: PubMed
    Score: 0.010
  55. Persaud S, Al Hadidi S, Anderson TS, Gallagher G, Chimonas S, Korenstein D, Mitchell AP. Industry Payments to Physicians Endorsing Drugs and Devices on a Social Media Platform. JAMA. 2024 06 25; 331(24):2131-2134.
    View in: PubMed
    Score: 0.010
  56. Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024 03 01; 109(3):906-914.
    View in: PubMed
    Score: 0.010
  57. Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD, Zhan F. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024 Jan 19; 15(1):615.
    View in: PubMed
    Score: 0.010
  58. Sun F, Cheng Y, Chen JR, Wanchai V, Mery DE, Xu H, Gai D, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J Clin Invest. 2024 Jan 02; 134(1).
    View in: PubMed
    Score: 0.010
  59. Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin GR. Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA Netw Open. 2023 11 01; 6(11):e2342195.
    View in: PubMed
    Score: 0.010
  60. Chakraborty R, Al Hadidi S, Cliff ERS, Mohyuddin GR. Is aggressive treatment of smoldering myeloma the path to curing myeloma? Blood Adv. 2023 08 08; 7(15):3932-3935.
    View in: PubMed
    Score: 0.009
  61. Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023 06 29; 16(1):70.
    View in: PubMed
    Score: 0.009
  62. Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 06 27; 7(12):2746-2757.
    View in: PubMed
    Score: 0.009
  63. Mohan M, Gong Z, Ashby TC, Al Hadidi S, Thanendrarajan S, Schinke C, Alapat D, Shaughnessy JD, Zhan F, van Rhee F, Sawyer JR, Tian E, Zangari M. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023 08 15; 129(16):2491-2498.
    View in: PubMed
    Score: 0.009
  64. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. 2023 03; 200(5):587-594.
    View in: PubMed
    Score: 0.009
  65. Schinke C, Poos AM, Bauer M, John L, Johnson S, Deshpande S, Carrillo L, Alapat D, Rasche L, Thanendrarajan S, Zangari M, Al Hadidi S, van Rhee F, Davies F, Raab MS, Morgan G, Weinhold N. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood Adv. 2022 11 22; 6(22):5873-5883.
    View in: PubMed
    Score: 0.009
  66. Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. Am J Hematol. 2022 12; 97(12):E451-E453.
    View in: PubMed
    Score: 0.009
  67. Fatoki RA, Koehn K, Kelkar A, Al Hadidi S, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, Mohyuddin GR. Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO Glob Oncol. 2022 08; 8:e2200119.
    View in: PubMed
    Score: 0.009
  68. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 07; 97(7):E276-E280.
    View in: PubMed
    Score: 0.009
  69. Mohan M, Gundarlapalli S, Szabo A, Yarlagadda N, Kakadia S, Konda M, Jillella A, Fnu A, Ogunsesan Y, Yarlagadda L, Thalambedu N, Munawar H, Graziutti M, Al Hadidi S, Alapat D, Thanendrarajan S, Zangari M, van Rhee F, Schinke C. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. Am J Hematol. 2022 06 01; 97(6):E195-E198.
    View in: PubMed
    Score: 0.009
  70. Caro J, Al Hadidi S, Usmani S, Yee AJ, Raje N, Davies FE. How to Treat High-Risk Myeloma at Diagnosis and Relapse. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:291-309.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.